drugset / Trial / NCT01907360

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

NCT01907360

Phase 1/2 Completed 29 enrolled Ironshore Pharmaceuticals and Development, Inc
Non-randomizedSequentialOpen-labelTreatment

Summary

This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.

Timeline

Start
2013-08
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 54 mg Oral